Updates are available Correction dated 2023-03-15
Click to view Correction: https://doi.org/10.1038/s41388-023-02615-8
-
Authors
Bello Roufai, D. http://orcid.org/0000-0002-2817-7866
Gonçalves, A.
De La Motte Rouge, T.
Akla, S.
Blonz, C.
Grenier, J.
Gligorov, J.
Saghatchian, M.
Bailleux, C.
Simon, H.
Desmoulins, I.
Tharin, Z.
Renaud, E. http://orcid.org/0000-0002-4888-4509
Bertho, M.
Benderra, M-A
Delaloge, S. http://orcid.org/0000-0003-2106-9165
Robert, L.
Cottu, P.
Pierga, J. Y.
Loirat, D.
Bertucci, A.
Renouf, B.
Bidard, F. C. http://orcid.org/0000-0001-5932-8949
Lerebours, F.
-
Funding
Funding for this research was provided by:
Novartis Pharma Sas gave financial support to the institution for data collection and biometry
- License Information
-
More Information
Article History
Received: 8 October 2022
Revised: 13 December 2022
Accepted: 16 December 2022
First Online: 7 January 2023
Change Date: 15 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-023-02615-8
Competing interests
: Institut Curie, represented in this work by Dr Florence Lerebours, has been funded by Novartis. DBR: Travel accommodations expenses: Daiichi Sankyo; Lilly; GSK. AB, TDLMR, CB, SA, CB, MAB, ID, ZT, ER, JG, MS: no relationships to disclose. JG: Travel accommodations expenses: AstraZeneca; Esai. HS: Honoraria: Lilly; Pfizer; Tesaro. Consulting or advisory role: Lilly; Mundipharla; Mylan; Novartis; Pierre Fabre; Roche; Sandoz; Vifor Pharma. Travel accommodations expenses: AstraZeneca; Lilly; Mundipharma; Novartis; Pfizer; Roche. SD: Consulting or advisory role: AstraZeneca; Pierre Fabre. Research funding: AstraZeneca; Exact Sciences; Lilly; Novartis; Pfiizer; Puma Biotechnolohy; Roche/Genentech; Sanofi. Travel accommodations expenses: AstraZeneca; Pfizer; Roche. MB: Travel accommodations expenses: Pfizer. Paul Cottu: Honoraria: Lilly; NanoString Technologies; Novartis; Pfizer; Pierre Fabre; Roche. Consulting or Advisory role: Lilly; Pfizer; Roche/Genentech. Research funding: Novartis; Pfizer. Travel accommodations expenses: Novartis; Pfizer. AG: Research Funding: Abbvie; AstaZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cascadian Therapeutics; Lilly; Merus; MSD; Nektar; Novartis; Roche; Roche/Genentech; Sanofi/Aventis; Seattle Genetics. Travel accommodations expenses: Novartis. DL: Consulting or Advisory role: MSD Travel accommodations expenses: Bristol-Myers Squibb. JYP: Consulting or Advisory role or travel accommodations expenses: Pfizer, Lilly MSD, Roche, Novartis, AstraZeneca, Pierre Fabre, Servier, Daiichi et Ipsen. FCB: Consulting or advisory role: Archer; Lilly; Novartis; Pfizer; Radius Health; Sanofi. Speakers’ bureau: AstraZeneca; Novartis; Pfizer; Roche. Research Funding: Menarini Silicon Biosystems; Novartis; Pfizer; ProLynx; Roche; Servier. Patents, royalties, other intellectual property: ctDNA detection techniques. Travel accommodations expenses: Chugai Pharma; Novartis; Pfizer. FL: Travel accommodations expenses: Lilly; Novartis; Pfizer; Pierre Fabre; Roche.
